

doi: 10.13241/j.cnki.pmb.2021.08.026

早发冠心病患者血清锌 a2 糖蛋白、单核细胞趋化蛋白 -1 水平与血脂的关系及其影响因素分析*

张妍妍¹ 曹曦¹ 罗敏¹ 明静^{1Δ} 陈琳² 张兴莹¹

(1 四川大学华西医院宜宾医院检验科 四川 宜宾 644000; 2 四川省人民医院心内科 四川 成都 610072)

摘要 目的:分析早发冠心病(PCAD)患者血清锌 a2 糖蛋白(ZAG)、单核细胞趋化蛋白-1(MCP-1)水平与血脂的关系及其影响因素。**方法:**收集 2017 年 1 月-2019 年 12 月在我院经冠状动脉造影确诊的冠心病患者 184 例,其中 PCAD 患者 86 例(PCAD 组),非 PCAD 患者 98 例(NPCAD 组),再选取同期男性 <55 岁,女性 <65 岁健康体检者 86 例作为对照组。收集所有研究对象的基线资料并检测空腹血糖(FBG)、总胆固醇(TC)、低密度脂蛋白(LDL)、甘油三酯(TG)、高密度脂蛋白(HDL)、血清 ZAG、MCP-1 水平,采用 Pearson 相关性分析 ZAG、MCP-1 与血脂相关性。多因素 Logistic 回归分析 PCAD 的影响因素。**结果:**PCAD 组、NPCAD 组糖尿病史、高血压病史、冠心病家族史比例、体质指数(BMI)、FPG、TG、MCP-1 高于对照组,HDL、ZAG 水平低于对照组($P<0.05$),PCAD 组年龄、HDL、ZAG 水平低于 NPCAD 组,冠心病家族史、吸烟史比例高于 NPCAD 组($P<0.05$)。Pearson 相关性分析结果表明,PCAD 患者 ZAG 与 HDL 呈正相关,MCP-1 与 HDL 呈负相关($P<0.05$);多因素 Logistic 回归分析显示,高血压、吸烟史、冠心病家族史、HDL、TG、ZAG、MCP-1 是 PCAD 的独立危险因素。**结论:**PCAD 患者 MCP-1 水平升高、ZAG、HDL 水平降低,MCP-1、ZAG 与 HDL 密切相关,且是 PCAD 的独立危险因素。

关键词:早发冠心病; 锌 a2 糖蛋白; 单核细胞趋化蛋白 -1; 血脂; 危险因素

中图分类号:R541.4 **文献标识码:**A **文章编号:**1673-6273(2021)08-1521-04

Relationship between Serum Zinc a2 Glycoprotein and Monocyte Chemotactic Protein-1 Levels and Blood Lipids in Patients with Premature Coronary Artery Disease and Analysis of Influencing Factors*

ZHANG Yan-yan¹, CAO Xi¹, LUO Min¹, MING Jing^{1Δ}, CHEN Lin², ZHANG Xing-ying¹

(1 Department of Laboratory, Yibin Hospital of West China Hospital of Sichuan University, Yibin, Sichuan, 644000, China;

2 Department of Cardiology, Sichuan Provincial People's Hospital, Chengdu, Sichuan, 610072, China)

ABSTRACT Objective: To analyze the relationship between serum zinc a2 glycoprotein (ZAG), monocyte chemotactic protein-1 (MCP-1) levels and blood lipids and their influencing factors in patients with premature coronary artery disease (PCAD). **Methods:** 84 patients with coronary heart disease diagnosed by coronary angiography in our hospital from January 2017 to December 2019 were collected, including 86 patients with PCAD (PCAD group) and 98 patients with non PCAD patients (NPCAD group). Then, 86 healthy patients with male <55 years old and female <65 years old during the same period were selected as the control group. Baseline data of all subjects were collected and levels of fasting blood glucose(FBG), total cholesterol(TC), triglyceride(TG), low-density lipoprotein(LDL), high-density lipoprotein (HDL), serum ZAG, MCP-1 were measured. Pearson correlation was used to analyze the correlation between ZAG, MCP-1 and blood lipid. Multivariate Logistic regression was used to analyze the influencing factors of PCAD. **Results:** Diabetes history, hypertension history, family history of coronary heart disease, body mass index (BMI), FPG, TG, MCP-1 in the PCAD group, NPCAD group were higher than control group, the levels of HDL, ZAG were lower than control group ($P<0.05$). The age and levels of HDL, ZAG levels in the PCAD group were lower than the NPCAD group, the proportion of family history of coronary heart disease and smoking history was higher than the NPCAD group($P<0.05$). Pearson correlation analysis results showed that ZAG was positively correlated with HDL, and MCP-1 was negatively correlated with HDL ($P<0.05$). Multivariate Logistic regression analysis showed that hypertension, smoking history, family history of coronary heart disease, HDL, TG, ZAG and MCP-1 were independent risk factors for PCAD. **Conclusions:** In patients with PCAD, MCP-1 levels increase, ZAG, HDL levels decrease, MCP-1, ZAG and HDL are closely related, and they are independent risk factors for PCAD.

Key words: Premature coronary artery disease; Zinc a2 glycoprotein; Monocyte chemoattractant protein-1; Blood fat; Risk factor

Chinese Library Classification(CLC): R541.4 **Document code:** A

Article ID: 1673-6273(2021)08-1521-04

* 基金项目:国家自然科学基金项目(30871233);四川省卫生计生委科研项目(20171775)

作者简介:张妍妍(1984-),女,本科,主管检验师,研究方向:检验医学,E-mail: zyybest168@163.com

Δ 通讯作者:明静(1985-),女,本科,副主任检验师,研究方向:检验医学,E-mail: mj603520026@126.com

(收稿日期:2020-10-21 接受日期:2020-11-16)

前言

冠心病的发病率逐年增加,且呈现年轻化的趋势,其中发病年龄男性小于 55 岁,女性小于 65 岁称为早发冠心病(PCAD)^[1]。PCAD 增加不良心血管不良事件和死亡率^[2]。发展中国家 PCAD 的患病率达到 31%^[3]。早期对 PCAD 危险因素有效干预,能够降低 PCAD 发病率和减少继发心血管疾病的发生,故寻找简单、可靠的血清学标志物对预防 PCAD 的发生或延缓疾病的进展具有重要意义。血脂代谢异常是 PCAD 的危险因素^[4]。血清载脂蛋白 a2 糖蛋白(ZAG)是一种新型的脂肪细胞因子,可以促进脂肪分解和利用,抑制脂肪合成,减少脂肪积聚,并参与了体重、能量代谢、脂质代谢平衡的调节过程^[5]。单核细胞趋化蛋白-1(MCP-1)主要由巨噬细胞和内皮细胞产生,趋化和激活单核细胞至炎症部位,活化成为巨噬细胞,与低密度脂蛋白结合转变为巨噬细胞源性泡沫细胞,具有促进炎症应答、血管平滑肌细胞的增殖、动脉粥样硬化斑块形成的作用^[6]。本文通过分析 PCAD 患者的 ZAG、MCP-1 水平与血脂的关系及其影响因素,从而为 PCAD 的诊断及治疗方案提供依据。

1 资料与方法

1.1 研究对象

收集 2017 年 1 月-2019 年 12 月在我院经冠状动脉造影确诊的冠心病患者 184 例,再根据年龄将患者分成 PCAD 组(男性<55 岁,女性<65)和非 PCAD 组(NPCAD 组)(男≥ 55 岁,女≥ 65 岁),其中 PCAD 组 86 例,NPCAD 组 98 例。纳入标准:①符合冠心病诊断^[7];②患者意识清晰,无精神及言语障碍,可正常沟通交流;③临床资料完整;④患者知情同意,自愿参加本研究。排除标准:①风心病、先心病、心肌病、肺心病、单纯心律失常、瓣膜病等其他器质性心脏病;②肝、肾功能异常;③合

并严重感染、代谢性疾病,脑血管病变;④入院前口服降脂药物者。再选取同期男性 <55 岁,女性 <65 岁健康体检者 86 例,作为对照组。三组研究对象基线资料的比较见表 1。

1.2 观察指标

1.2.1 收集一般资料 记录所有研究对象性别、年龄、疾病史、吸烟等。测量所有研究对象身高、体重,计算体质质量指数(BMI)。

1.2.2 血清学指标的检测 采集研究对象晨起空腹采静脉血 5 mL,以 3000 转/min 转速,半径 20 cm,时间 20 min,离心后取血清,置于冰箱(-40℃)中保存备用,检测空腹血糖(FBG)、总胆固醇(TC)、低密度脂蛋白(LDL)、甘油三酯(TG)、高密度脂蛋白(HDL)等常规实验室指标。酶联免疫吸附法检测 ZAP、MCP-1 水平。具体操作严格按试剂盒说明书进行。BS-220 全自动生化分析仪由迈瑞公司提供。酶联免疫试剂盒购自武汉默沙克生物制剂有限公司。

1.3 统计学方法

数据应用 SPSS20.0 统计软件分析。计量资料经检验符合正态分布,以($\bar{x} \pm s$)表示,组间比较行 t 检验,多组间比较行单因素方差分析,以例或率表示计数资料,行 χ^2 检验。ZAP、MCP-1 与血脂间相关性采用 Pearson 相关性分析。PCAD 危险因素采用多因素 Logistic 回归分析。检验水准为 $\alpha=0.05$ 。

2 结果

2.1 基线资料比较

PCAD 组年龄低于 NPCAD 组,冠心病家族史、吸烟史比例高于 NPCAD 组($P<0.05$)。PCAD 组、NPCAD 组糖尿病史、高血压病史、冠心病家族史比例、BMI 高于对照组($P<0.05$)。见表 1。

表 1 三组研究对象基线资料比较

Table 1 Comparison of baseline data of three groups of subjects

Indexes	PCAD group(n=86)	NPCAD group(n=98)	Control group(n=86)	χ^2/F	P
Age(years old)	49.25± 4.72*	67.36± 5.24	51.39± 4.96	367.96	0.000
Male/female	55/31	52/46	44/42	0.147	0.634
Smoking history[n(%)]	45(52.33)*#	37(37.76)	30(34.83)	3.936	0.047
Diabetes history[n(%)]	16(18.60)#	33(33.67)#	9(10.46)	5.323	0.031
Hypertension history[n(%)]	31(36.05)#	61(62.24)#	13(15.12)	11.862	0.001
Family history of coronary heart disease[n(%)]	31(36.05)*#	18(18.37)#	8(9.30)	17.542	0.000
BMI(kg/m ²)	25.19± 2.16#	24.67± 2.28#	22.87± 1.86	28.715	0.000

Note: compared with control group, # $P<0.05$; compared with NPCAD group, * $P<0.05$.

2.2 三组血清学指标比较

PCAD 组、NPCAD 组 FPG、TG、MCP-1 高于对照组,HDL、ZAG 低于对照组,且 PCAD 组 HDL、ZAG 水平低于 NPCAD 组($P<0.05$),三组在 TC、LDL 水平差异无统计学意义($P>0.05$)。见表 2。

2.3 PCAD 患者 ZAG、MCP-1 与血脂指标的相关性分析

Pearson 相关性分析结果表明,PCAD 患者 ZAG 与 HDL

呈正相关,MCP-1 与 HDL 呈负相关($P<0.05$)。见表 3。

2.4 PCAD 的多因素 Logistic 回归分析

以 PCAD 为因变量,将年龄、吸烟史、BMI、高血压史、糖尿病史、冠心病家族史、HDL、TG、ZAG、MCP-1 纳入自变量,赋值如下:年龄 1=(50 岁≤ 男性 <55 岁,60 岁≤ 女性 <65 岁),0=(男性 <50 岁,女性 <60);吸烟史:1=是,0=否;高血压病史:1=有,0=否;冠心病家族史:1=有,0=否;糖尿病史:1=有,0=否;

BMI、HDL、TG、ZAG、MCP-1 按照实际数值输入。采用多因素 Logistic 回归分析,结果显示高血压病史、吸烟史、冠心病家族史、HDL 和 ZAG 水平降低,TG 和 MCP-1 升高是 PCAD 的独立危险因素($P<0.05$)。见表 4。

表 2 三组血清学指标比较($\bar{x} \pm s$)
Table 2 Comparison of serological indexes among three groups($\bar{x} \pm s$)

Indexes	PCAD group(n=86)	NPCAD group(n=98)	Control group(n=86)	F	P
FPG(mmol/L)	6.23± 1.32 [#]	6.76± 1.41 [#]	5.12± 0.83	42.263	0.000
TG(mmol/L)	2.12± 0.31 [#]	2.06± 0.34 [#]	1.21± 0.29	228.196	0.000
TC(mmol/L)	5.02± 1.07	5.06± 1.01	4.87± 0.83	0.939	0.392
HDL(mmol/L)	1.09± 0.68 ^{**}	1.23± 0.43 [#]	1.41± 0.53	7.288	0.001
LDL(mmol/L)	2.97± 0.72	2.94± 0.58	2.85± 0.41	0.991	0.373
MCP-1(pg/mL)	73.54± 20.11 [#]	71.24± 18.6 [#]	33.71± 14.82	134.42	0.000
ZAG(ug/mL)	7.23± 4.87 ^{**}	8.53± 4.92 [#]	8.81± 4.15	3.468	0.033

Note: compared with control group, [#] $P<0.05$; compared with NPCAD group, ^{*} $P<0.05$.

表 3 PCAD 患者 ZAG、MCP-1 与血脂指标相关性分析
Table 3 Correlation analysis of ZAG, MCP-1 and blood lipid in patients with PCAD

Indexes	ZAG		MCP-1	
	r	P	r	P
TG	0.153	0.127	-0.054	0.248
TC	0.093	0.259	-0.028	0.138
HDL	0.331	0.008	-0.433	0.003
LDL	0.162	0.086	-0.175	0.082

表 4 PCAD 的多因素 Logistic 回归分析
Table 4 Multivariate Logistic regression analysis of PCAD

Risk factors	B	SE	Wald χ^2	P	OR	95%CI
Hypertension history	1.232	0.065	2.268	0.028	3.469	2.136-4.735
Smoking history	0.085	0.017	3.166	0.004	1.286	1.083-2.115
Family history of coronary heart disease	0.286	0.003	3.287	0.003	1.345	1.123-2.347
HDL	0.376	0.329	4.567	0.000	4.237	2.213-6.782
TG	0.186	0.027	2.765	0.015	1.037	1.003-1.983
ZAG	1.123	0.484	11.286	0.000	2.956	1.257-7.129
MCP-1	0.456	0.227	8.368	0.000	3.862	2.286-6.781

3 讨论

随着生活水平、工作压力、生活方式等不良因素的增加,冠心病患者日渐呈年轻化发展。由于 PCAD 缺少明显的临床症状,且病情发展迅猛,多表现为急性冠脉综合征,病死率较高^[89]。PCAD 动脉粥样硬化斑块富含脂质泡沫细胞,为软斑块,易破损、进展迅速^[10-12]。冠心病患者的血脂指标与正常人相比存在一定差异,HDL 亚型与冠心病的发生、发展,患者病变程度紧密联系,可作为冠心病患者病情程度、预测终点事件的重要指标^[13]。目前,PCAD 并没有特异性的风险预测指标,研究证实 HDL 在 PCAD 急性冠脉综合征患者外周血中明显降低,可作为该病预测指标^[14]。MCP-1 在冠心病患者中高表达,有助于监测冠心病严重程度。ZAG 水平在急性冠脉综合征中明显升高,

有可能成为冠心病危险分层有价值的参考指标。PCAD 患者中 MCP-1、ZAG 表达与 HDL 是否具有相关性,其在 PCAD 中的作用机制仍在探索中。

本研究可见 PCAD 组、NPCAD 组 FPG、TG、MCP-1 高于对照组,HDL、ZAG 低于对照组,且 PCAD 组 HDL、ZAG 水平低于 NPCAD 组,提示 PCAD 患者更容易出现血脂异常,脂质代谢紊乱更为明显。在动脉粥样硬化进展过程中,HDL 可阻止泡沫细胞生成,低 HDL 是冠心病的独立危险因素,HDL 降低,则患者发生冠心病风险增高^[15-17]。ZAG 作为一种新型脂肪动员因子,在体内多种组织中表达,与脂肪细胞的分化、成熟、分解与利用相关,通过协调多种信号转导途径参与免疫应答、炎症反应及维持代谢稳态机体的生理过程,调控机体糖脂代谢,能量平衡,抑制炎症因子表达,抗动脉粥样硬化分子的失衡,已成

为动脉粥样硬化及其相关疾病研究的热点^[18-20]。既往研究表明^[21],PCAD患者血清ZAG水平降低,ZAG水平较低的群体更有可能患有PCAD,ZAG可能是PCAD患者的潜在诊断生物标志物,并且ZAG与年龄、性别、BMI、FBG、TC、HDL、肌酐和尿素等指标联合具有更高的诊断效能。MCP-1水平在PCAD组最高,对照组最低,提示在PCAD患者中,MCP-1大量诱导巨噬细胞的渗入,炎症反应更为活跃。MCP-1通过PI3K/Akt介导的ATP结合盒转运蛋白A1、ATP结合盒转运体G1和B类I型清道夫受体表达削弱HepG2细胞中逆向胆固醇转运能力,在动脉粥样硬化的多个阶段起着至关重要的作用^[24,25]。

本研究经相关性分析后发现MCP-1与HDL呈正相关,ZAG与HDL呈负相关,这是因为二者对脂质代谢的影响机制不同,ZAG通过负调节TNF- α 来减轻炎症,加速脂解,促进增殖和减少细胞凋亡^[26,27],故推测ZAG可能通过抗炎、抗泡沫细胞形成而对PCAD发挥影响。MCP-1加速炎症细胞向内膜的迁移,加剧动脉粥样硬化。MCP-1可能会协同HDL的炎症反应,促进HDL氧化从而形成软斑块,加速血管疾病发生及病程进展,增加PCAD发生的风险^[28,29]。多因素Logistic回归分析显示年龄、吸烟史、冠心病家族史、HDL及ZAG水平降低、TG及MCP-1水平升高是PCAD的独立危险因素。PCAD的危险因素错综复杂,既往荟萃分析结果显示年轻人的糖尿病,冠心病家族史,血脂异常,吸烟和高血压是冠心病危险因素^[30],本研究结果也与之相符。

综上所述,血清MCP-1、ZAG水平与HDL具有密切的相关性,MCP-1水平的升高及ZAG水平的降低可能促进PCAD发生和发展,二者均为PCAD发生的危险因素,或可作为PCAD的早期诊断指标和治疗的靶点。

参考文献(References)

- Collet JP, Zeitouni M, Procopi N, et al. Long-Term Evolution of Premature Coronary Artery Disease[J]. *J Am Coll Cardiol*, 2019, 74(15): 1868-1878
- Osadnik T, Pawlas N, Osadnik K, et al. Progesterone levels are associated with family history of premature coronary artery disease in young healthy adult men[J]. *PLoS One*, 2019, 14(4): e0215302
- 张健,马腾,李晓,等.河北省邢台市市干部职工冠心病危险因素及归因分析[J]. *中国心血管杂志*, 2020, 25(3): 263-266
- 代中礼,汪芳松,钱福东,等.血脂及其比值与早发冠心病的相关性分析[J]. *当代医学*, 2016, 22(5): 8-9
- Romauch M. Zinc- α 2-glycoprotein is an inhibitor of amine oxidase copper-containing 3[J]. *Open Biol*, 2019, 9(7): 190035
- Lennard Richard ML, Nowling TK, Brandon D, et al. Fli-1 controls transcription from the MCP-1 gene promoter, which may provide a novel mechanism for chemokine and cytokine activation [J]. *Mol Immunol*, 2015, 63(2): 566-573
- Scanlon PJ, Faxon DP, Audet AM, et al. ACC/AHA Guidelines for coronary angiography[J]. *Circulation*, 1999, 99(8): 2345-2357
- Sheikhvatan M, Boroumand MA, Behmanesh M, et al. Association of R279Q and C1562T polymorphisms of matrix metalloproteinase 9 gene and increased risk for myocardial infarction in patients with premature coronary artery disease[J]. *Clin Lab Anal*, 2018, 32(1): e22218
- Hamad R, Penko J, Kazi DS, et al. Association of Low Socioeconomic Status With Premature Coronary Heart Disease in US Adults [J]. *JAMA Cardiol*, 2020, 5(8): 899-908
- Faghihi S, Vasheghani-Farahani A, Parsaee M, et al. Association Between Epicardial Fat Thickness and Premature Coronary Artery Disease: A Case Control Study [J]. *Res Cardiovasc Med*, 2015, 4(2): e25679
- Xie J, Qi J, Mao H, et al. Coronary plaque tissue characterization in patients with premature coronary artery disease [J]. *Int J Cardiovasc Imaging*, 2020, 36(6): 1003-1011
- Bossard M, Latifi Y, Fabbri M, et al. Increasing Mortality From Premature Coronary Artery Disease in Women in the Rural United States [J]. *J Am Heart Assoc*, 2020, 9(9): e015334
- 蒋晓发,邱丽君,周刚,等. HDL-C及其亚型与冠心病患者预后关系的相关性研究[J]. *现代生物医学进展*, 2018, 18(11): 2158-2161
- 温伟谊,张舒媚,刘晓剑,等. hsCRP、apoB/apoA1、血脂表达与早发冠心病急性冠脉综合征的关系 [J]. *中国循证心血管医学杂志*, 2019, 11(3): 344-348
- 张宁,刘文娟. 高密度脂蛋白胆固醇与冠状动脉粥样硬化性心脏病及冠状动脉多支病变的相关性研究 [J]. *中国医药*, 2019, 14(7): 969-972
- Cardner M, Yalcinkaya M, Goetze S, et al. Structure-function relationships of HDL in diabetes and coronary heart disease [J]. *JCI Insight*, 2020, 5(1): e131491
- 吴和弟,许丽娃,吉家钗,等. 2型糖尿病合并冠心病患者血清PCT、hs-CRP及血脂水平与冠状动脉病变的关系分析 [J]. *疑难病杂志*, 2018, 17(10): 1094-1098
- Elsheikh M, Elhefnawy KA, Emad G, et al. Zinc alpha 2 glycoprotein as an early biomarker of diabetic nephropathy in patients with type 2 diabetes mellitus[J]. *J Bras Nefrol*, 2019, 41(4): 509-517
- Huang D, Mao X, Peng J, et al. Role of adipokine zinc- α 2-glycoprotein in coronary heart disease [J]. *Am J Physiol Endocrinol Metab*, 2019, 317(6): E1055-E1062
- Hamedifard Z, Farrokhian A, Reiner Z, et al. The effects of combined magnesium and zinc supplementation on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease [J]. *Lipids Health Dis*, 2020, 19(1): 112
- Liu M, Zhu H, Zhai T, et al. Serum Zinc- α 2-Glycoprotein Levels Were Decreased in Patients With Premature Coronary Artery Disease [J]. *Front Endocrinol (Lausanne)*, 2019, 29(10): 197
- 张艳,雷雨婷,周权,等. 冠心病患者血清MCP-1、MPO水平变化及意义[J]. *山东医药*, 2015, 55(23): 73-75
- Abedimanesh N, Motlagh B, Abedimanesh S, et al. Effects of crocin and saffron aqueous extract on gene expression of SIRT1, AMPK, LOX1, NF- κ B, and MCP-1 in patients with coronary artery disease: A randomized placebo-controlled clinical trial [J]. *Phytother Res*, 2020, 34(5): 1114-112
- 李国敏. 血清IL-6、TNF- α 、MCP-1联合检测在冠心病临床诊断中的应用价值[J]. *检验医学与临床*, 2019, 16(24): 3683-3685
- Huang CX, Zhang YL, Wang JF, et al. MCP-1 impacts RCT by repressing ABCA1, ABCG1, and SR-BI through PI3K/Akt posttranslational regulation in HepG2 cells [J]. *J Lipid Res*, 2013, 54(5): 1231-1240

- [8] Zytoon AA, Mohammed HH, Hosny DM. The Role of Magnetic Resonance Cholangiopancreatography in Diagnosis of Hepatobiliary Lesions[J]. J Med Imaging Radiat Sci, 2016, 47(1): 66-73
- [9] Wang W, Xu X, Tian B, et al. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer[J]. Clin Chim Acta, 2017, 470(7): 51-55
- [10] 滕才钧, 邓燕云, 韦建林. 18 氟 - 氟代脱氧葡萄糖正电子发射断层显像 / 计算机断层成像联合磁共振胰胆管造影异机融合显像在梗阻性黄疸诊断中的应用[J]. 广西医学, 2019, 41(11): 1356-1359
- [11] Ocak Serin S, Isiklar A, Cakit H, et al. A case of tuberculosis presented by obstructive jaundice tuberculosis-related mechanical icterus [J]. J Infect Dev Ctries, 2020, 14(10): 1221-1224
- [12] Bozbulut NE, Akdulum i, San S, et al. Obstructive jaundice and severe pancreatitis due to the foramen of Winslow hernia with multiple anomalies[J]. Turk J Pediatr, 2020, 62(1): 152-155
- [13] 李雪, 孙玉明, 龙云辉, 等. 经皮肝穿刺胆道引流术与逆行胰胆管造影术对结石性梗阻性黄疸患者的疗效比较研究[J]. 现代生物医学进展, 2019, 19(5): 851-854, 889
- [14] Li W, Wang X, Wang Z, et al. The role of seed implantation in patients with unresectable pancreatic carcinoma after relief of obstructive jaundice using ERCP[J]. Brachytherapy, 2020, 19(1): 97-103
- [15] Sato J, Ishiwatari H, Ashida R, et al. Primary non-ampullary duodenal follicular lymphoma presenting with, obstructive, jaundice[J]. Clin J Gastroenterol, 2020, 13(2): 214-218
- [16] Li J, Zhuo S, Chen B, et al. Clinical efficacy of laparoscopic modified loop cholecystojejunostomy for the treatment of malignant obstructive jaundice[J]. J Int Med Res, 2020, 48(2): 285-287
- [17] Kakaei F, Fasihi M, Hashemzadeh S, et al. Effect of N-acetylcysteine on liver and kidney function tests after surgical bypass in obstructive jaundice: A randomized controlled trial[J]. Asian J Surg, 2020, 43(1): 322-329
- [18] Feng Y, Zhang S, Guo T, et al. Validity and safety of corticosteroids alone without biliary stenting for obstructive jaundice in autoimmune pancreatitis[J]. Pancreatology, 2020, 20(8): 1793-1795
- [19] Achufusi TG, Sharma A, Sapkota B. Multiple myeloma presenting as plasmacytoma causing obstructive jaundice[J]. Proc (Bayl Univ Med Cent), 2020, 33(2): 266-267
- [20] Hanif H, Khan SA, Muneer S, et al. Diagnostic accuracy of ultrasound in evaluation of obstructive jaundice with MRCP as gold standard[J]. Pak J Med Sci, 2020, 36(4): 652-656
- [21] Imam S, Islam MN, Khan NA, et al. Magnetic Resonance Cholangiopancreatography (MRCP) Evaluation of Obstructive Jaundice in Comparison with Endoscopic Retrograde Cholangiopancreatography (ERCP)[J]. Mymensingh Med J, 2017, 26(2): 420-425
- [22] 马晓兵, 李瀛, 张彬彬. 磁共振胰胆管成像对阻塞性黄疸的诊断价值[J]. 临床军医杂志, 2014, 42(8): 789-792
- [23] 郭小华. MRI, MRCP 在梗阻性黄疸诊断中的应用价值 [J]. 中国 CT 和 MRI 杂志, 2019, 17(7): 103-106
- [24] 刘远高, 李昌松. 18F-FDG PET/CT 与 MRI 诊断梗阻性黄疸的临床价值比较[J]. 海南医学, 2018, 29(21): 3044-3047
- [25] 庞华春, 傅健, 李双佐. 四种肿瘤标志物联合检测鉴别肿瘤梗阻性黄疸的价值[J]. 广州医科大学学报, 2014, 42(5): 32-35
- [26] Chen R, Jiang C, Zhu Q, et al. Combining the tumor abnormal protein test with tests for carcinoembryonic antigens, cancer antigen 15-3, and/or cancer antigen 125 significantly increased their diagnostic sensitivity for breast cancer [J]. Medicine (Baltimore), 2020, 99(29): e21231
- [27] Zhou H, Dong A, Xia H, et al. Associations between CA19-9 and CA125 levels and human epidermal growth factor receptor 2 overexpression in patients with gastric cancer [J]. Oncol Lett, 2018, 16(1): 1079-1086
- [28] Milman S, Whitney KD, Fleischer N. Metastatic medullary thyroid cancer presenting with elevated levels of CA 19-9 and CA 125 [J]. Thyroid, 2011, 21(8): 913-916
- [29] Okazaki S, Baba H, Iwata N, et al. Carcinoembryonic antigen testing after curative liver resection for synchronous liver metastasis of colorectal cancer: a Japanese multicenter analysis [J]. Surg Today, 2017, 47(10): 1223-1229
- [30] 肖来华, 计学理. 高场强 MRCP 联合肿瘤标志物检测对梗阻性黄疸的诊断价值[J]. 中国误诊学杂志, 2011, 11(18): 4390-4391

(上接第 1524 页)

- [26] Liu T, Luo X, Li ZH, et al. Zinc- α 2-glycoprotein 1 attenuates non-alcoholic fatty liver disease by negatively regulating tumour necrosis factor- α [J]. World J Gastroenterol, 2019, 25(36): 5451-5468
- [27] Nezlobinsky T, Solovyova O, Panfilov AV. Anisotropic conduction in the myocardium due to fibrosis: the effect of texture on wave propagation[J]. Sci Rep, 2020, 10(1): 764
- [28] Sun RL, Huang CX, Bao JL, et al. CC-Chemokine Ligand 2 (CCL2) Suppresses High Density Lipoprotein (HDL) Internalization and Cholesterol Efflux via CC-Chemokine Receptor 2 (CCR2) Induction and p42/44 Mitogen-activated Protein Kinase (MAPK) Activation in Human Endothelial Cells [J]. J Biol Chem, 2016, 291(37): 19532-19544
- [29] 张舒媚, 包金兰, 孙润, 等. 早发冠心病患者血清 MCP-1 与 HDL2、HDL3 水平及其相关性分析[J]. 中山大学学报(医学科学版), 2015, 36(3): 403-407
- [30] Poorzand H, Tsarouhas K, Hozhabrossadati SA, et al. Risk factors of premature coronary artery disease in Iran: A systematic review and meta-analysis[J]. Eur J Clin Invest, 2019, 49(7): e13124